Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/33090
Title: | Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience. | Austin Authors: | Bahig, Houda;Ehab, Hanna Y;Garden, Adam S;Ng, Sweet Ping ;Frank, Steven J;Nguyen, Theresa;Gunn, Gary B;Rosenthal, David I;Fuller, Clifton D;Ferrarotto, Renata;Bell, Diana;Su, Shirley;Phan, Jack | Affiliation: | Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.;Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada. Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. Radiation Oncology Olivia Newton-John Cancer Wellness and Research Centre Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. |
Issue Date: | Jul-2023 | Date: | 2023 | Publication information: | Head & Neck 2023-07; 45(7) | Abstract: | To report long-term outcomes of modern radiotherapy for sinonasal cancers. A retrospective analysis of patients with sinonasal tumors treated with intensity-modulated radiotherapy or proton therapy. Multivariate analysis was used to determine predictive variables of progression free survival (PFS) and overall survival (OS). Three hundred and eleven patients were included, with median follow-up of 75 months. The most common histologies were squamous cell (42%), adenoid cystic (15%), and sinonasal undifferentiated carcinoma (15%). Induction chemotherapy was administered to 47% of patients; 68% had adjuvant radiotherapy. Ten-year local control, regional control, distant metastasis free survival, PFS, and overall survival rates were 73%, 88%, 47%, 32%, and 51%, respectively. Age, non-nasal cavity tumor site, T3-4 stage, neck dissection, and radiation dose were predictive of PFS, while age, non-nasal cavity tumor site, T3-4 stage, positive margins, neck dissection, and use of neoadjuvant chemotherapy were predictive of OS. There was a 13% rate of late grade ≥3 toxicities. This cohort of patients with sinonasal cancer treated with modern radiotherapy demonstrates favorable disease control rate and acceptable toxicity profile. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/33090 | DOI: | 10.1002/hed.27381 | ORCID: | 0000-0001-9508-0602 0000-0001-7926-2641 0000-0001-6517-7884 0000-0002-5264-3994 0000-0002-3561-215X 0000-0002-3903-8204 0000-0001-5977-6004 |
Journal: | Head & Neck | Start page: | 1692 | End page: | 1703 | PubMed URL: | 37165701 | ISSN: | 1097-0347 | Type: | Journal Article | Subjects: | IMPT IMRT SCC SNUC VMAT conformal radiotherapy head and neck cancer intensity modulated radiation therapy paranasal sinus cancer proton therapy radiation therapy radiotherapy sinonasal tumors Paranasal Sinus Neoplasms/pathology Nose Neoplasms/pathology Maxillary Sinus Neoplasms/pathology Radiotherapy, Intensity-Modulated/methods |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.